Injectable Targeted Therapy Market Report 2026

Injectable Targeted Therapy Market Overview

• Injectable Targeted Therapy market size has reached to $64.22 billion in 2025 • Expected to grow to $105.2 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Increasing Demand For Personalized Medicine Driving The Market Due To Advances In Genomics And Tailored Treatment Approaches • Market Trend: Innovative Injectable Solutions For Improved Drug Delivery And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Injectable Targeted Therapy Market?

Injectable targeted therapy involves medications given through injection that precisely target specific proteins or cells responsible for a disease. It aims to treat conditions such as cancer, more effectively while reducing damage to healthy tissues compared to conventional treatments. The main types of injectable targeted therapy are monoclonal antibodies, small molecules, immunotoxins, and others. Monoclonal antibodies refers to lab-engineered antibodies designed to bind specifically to target proteins on diseased cells. The primary mechanisms of action involve targeted inhibition of signal transduction pathways, targeted delivery of cytotoxic agents, and immunomodulation. These therapies are commonly administered intravenously, subcutaneously, and intramuscularly. They are applied across diverse fields such as oncology, cardiometabolism, immunology, infectious diseases, neuroscience, ophthalmology, and others, serving end users including hospitals, specialty clinics, and research laboratories.

What Is The Injectable Targeted Therapy Market Growth Forecast?

The injectable targeted therapy market size is expected to see rapid growth in the next few years. It will grow to $105.2 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing approvals of targeted injectable therapies, rising investments in personalized medicine, expansion of biologics manufacturing capacity, growing focus on immunotherapy development, increasing demand for precision treatment protocols. Major trends in the forecast period include increasing development of precision oncology injectables, rising adoption of antibody-based therapeutics, growing focus on targeted drug delivery systems, expansion of combination injectable therapies, enhanced emphasis on reduced off-target toxicity.

Global Injectable Targeted Therapy Market Segmentation

1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types 2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation 3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular 4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications 5) By End User: Hospitals, Specialty Clinics, Research Laboratories Subsegments: 1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies 2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors 3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins 4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics

What Is The Driver Of The Injectable Targeted Therapy Market?

The increasing demand for personalized medicine is expected to propel the growth of the injectable targeted therapy market going forward. Personalized medicine refers to a healthcare approach that tailors prevention, diagnosis, and treatment to an individual’s genetic, environmental, and lifestyle factors. Increasing personalized medicine is driven by advances in genomics, allowing deeper understanding of individual genetic variations and enabling more precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Injectable targeted therapy enables personalized medicine by delivering drugs that specifically target a patient’s unique molecular or genetic disease profile, improving efficacy and minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the injectable targeted therapy industry.

Key Players In The Global Injectable Targeted Therapy Market

Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.

Global Injectable Targeted Therapy Market Trends and Insights

Major companies operating in the injectable targeted therapy market are focusing on developing innovative solutions such as subcutaneous injection to improve drug delivery efficiency, enhance patient compliance, and target specific disease pathways more effectively. Subcutaneous injection refers to a method of administering medication under the skin into the fatty tissue just beneath the dermis, allowing the drug to be absorbed slowly into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company partnered with Biogen Inc., a US-based biotechnology company, and received approval from the FDA for LEQEMBI IQLIK, a treatment for early Alzheimer's disease. It is a convenient, once-weekly subcutaneous injection for maintenance treatment of early Alzheimer's disease, allowing patients to self-administer at home after initial intravenous therapy. It helps slow cognitive decline by targeting and clearing amyloid beta plaques and protofibrils, key drivers of Alzheimer's progression. This formulation reduces treatment time, lowers systemic side effects compared to IV infusions, and lessens the need for infusion center visits, offering greater independence for patients and care partners.

What Are Latest Mergers And Acquisitions In The Injectable Targeted Therapy Market?

In September 2025, Novartis AG, a Switzerland-based pharmaceutical corporation, acquired Tourmaline Bio Inc. for an undisclosed amount. With this acquisition Novartis AG aims to strengthen and diversify its cardiovascular portfolio by adding pacibekitug, a novel anti-inflammatory therapy targeting IL-6 to address residual inflammatory risk in atherosclerotic cardiovascular disease, positioning itself at the forefront of inflammation-driven cardiovascular treatments and capturing a high-growth market opportunity. Tourmaline Bio Inc. is a US-based biotechnology company that offers an injectable targeted therapy.

Regional Insights

North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Injectable Targeted Therapy Market?

The injectable targeted therapy market consists of sales of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Injectable Targeted Therapy Market Report 2026?

The injectable targeted therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the injectable targeted therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.